$ADMA News

ADMA Biologics (ADMA) Hit With Federal Securities Lawsuit Over Revenue Inflation Allegations

Adma Biologics (ADMA) Dips More Than Broader Market: What You Should Know

Adma Biologics (ADMA) Stock Dips While Market Gains: Key Facts

ADMA Biologics (ADMA) Valuation After 2026 Guidance Reset And BIVIGAM Headwinds

ADMA Biologics (ADMA) Receives FDA Label Expansion for ASCENIV

Is ADMA Biologics, Inc. (ADMA) Among the Best Russell 2000 Stocks to Invest In According to Hedge Funds?

ADMA Biologics: Longstanding Bull Hits The Reset Button After Murky Q1 Earnings

Can Asceniv Help ADMA Navigate the Current IG Market Challenges?

Is it Time to Exit ADMA Biologics Stock After a 22% Monthly Plunge?

How Channel Stuffing Probes and ASCENIV’s Pediatric Expansion Will Impact ADMA Biologics (ADMA) Investors

Here’s What Analysts Think About ADMA Biologics (ADMA)

Is Adma Biologics (ADMA) a Buy as Wall Street Analysts Look Optimistic?

Canaccord Cuts PT on ADMA Biologics Inc. (ADMA) But Remains a Buy on Shares

Canaccord Genuity Maintains Buy on ADMA Biologics, Lowers Price Target to $18

Mizuho Maintains Outperform on ADMA Biologics, Lowers Price Target to $20

ADMA Biologics, Inc. (ADMA) Q1 2026 Earnings Call Transcript

ADMA Biologics (NASDAQ:ADMA) Shares Plunge on Q1 Miss and Revenue Guidance Cut

ADMA Biologics Sees FY2026 Sales $530.000M-$560.000M vs $632.367M Est

ADMA Biologics Q1 Adj. EPS $0.17 Misses $0.20 Estimate, Sales $114.493M Miss $141.800M Estimate

ADMA Biologics Announces FDA Approval Of The Company's Supplemental Biologics License Application Submitted Under Section 351(a) Of The Public Health Service Act For ASCENIV